TrialNCT04025879
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- Status
- ACTIVE NOT RECRUITING
- Phase
- PHASE3
- Last update posted
- 08/26/2026
- Start
- 11/05/2019
- Sponsor
- Bristol-Myers Squibb
- Specialties
- oncology
Conditions: Carcinoma, Non-Small-Cell Lung
Brief summary
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.